Solara Active Pharma Sciences Ltd, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. Founded in 2017, the company has quickly established itself as a key provider of high-quality products, catering to both domestic and international markets. With a focus on innovation and sustainability, Solara offers a diverse range of APIs, particularly in the therapeutic areas of anti-infectives, cardiovascular, and central nervous system medications. The company’s commitment to quality and regulatory compliance has earned it a strong market position, with notable achievements in securing approvals from major global regulatory bodies. Solara's strategic operational regions extend across Asia, Europe, and the Americas, reinforcing its status as a trusted partner in the pharmaceutical supply chain.
How does Solara Active Pharma Sciences Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Solara Active Pharma Sciences Ltd's score of 18 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Solara Active Pharma Sciences Ltd reported total carbon emissions of approximately 54,428,000 kg CO2e, comprising 11,168,000 kg CO2e from Scope 1 and 43,425,000 kg CO2e from Scope 2. The company has shown consistency in its emissions data, with similar figures reported in 2022, where total emissions were about 60,622,000 kg CO2e, including 10,169,000 kg CO2e from Scope 1 and 50,693,000 kg CO2e from Scope 2. Despite these figures, Solara has not disclosed any specific reduction targets or initiatives aimed at decreasing its carbon footprint. The absence of Science-Based Targets Initiative (SBTi) commitments or other formal climate pledges indicates a potential area for improvement in their climate strategy. The company’s emissions data is not cascaded from any parent organization, and all reported figures are directly attributed to Solara Active Pharma Sciences Ltd. As the organisation continues to grow, it may benefit from establishing clear climate commitments to enhance its sustainability profile and align with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | 2023 | |
---|---|---|---|
Scope 1 | 10,169,000 | 00,000,000 | 00,000,000 |
Scope 2 | 50,693,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Solara Active Pharma Sciences Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.